patent dispute12 Mar 2020 11:49
i think the current price decline is due to the perceived delay in the US deal and also current market uncertainty which is effecting ALL stocks.
However, as the patent question has been raised here so i thought i do some digging.
STX has 2 patents that run until 2032 and 3205 respectively - see details below.
Teva has appealed these decisions, but thus far very little seems to have happened. There are no details on the appeal as this process has not completed. From experience of similar appeals it is often used for clarification purposes regarding the extent of the patent.
The main one is #2 668 175 which was appealed on 16/5/19 and on 13/8/19 a statement of grounds was filed. STX RNSed this in early June 2019.
This patent DOES cover China (code CN) so the fact we have recently signed a deal with China is a massive positive IMHO.
# 3 160 951 seems a lesser issue and it lists 23/6/20 as the date of oral proceedings.
So IMHO this is a bit of a red herring - STX cannot make any comment as the process is out of their control. The Chinese deal has only recently been signed and FDA approval is a massive hurdle for any competitors, if any exist. IMHO it's business as usual.
The Group has been made aware that a 3rd party has raised objections with the European Patent Office (EPO) to the Group's patents (#2 668 175 and # 3 160 951) which cover "Process for preparing an iron hydroxypyrone" and "Crystalline forms of ferric maltol" respectively. On the basis of specialist advice received and the fact both patents went through an extensive examination process prior to grant, the Group continues to have full confidence in the validity of the patents which expire in 2032 and 2035, and intends to robustly defend its intellectual property, if required. Further information is available on the website of the European Patent Office (EPO) (www.epo.org) and the Group will provide updates in due course.